US Bancorp DE Sells 29,405 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

US Bancorp DE lessened its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 38.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,255 shares of the company’s stock after selling 29,405 shares during the quarter. US Bancorp DE’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $1,218,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of FMS. TD Waterhouse Canada Inc. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter valued at about $36,000. Atlantic Union Bankshares Corp acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at about $43,000. Hantz Financial Services Inc. boosted its stake in Fresenius Medical Care AG & Co. KGaA by 568.5% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after purchasing an additional 1,768 shares during the last quarter. Huntington National Bank increased its holdings in Fresenius Medical Care AG & Co. KGaA by 219.5% during the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after purchasing an additional 1,618 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $73,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock opened at $23.03 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.92 and a current ratio of 1.26. The firm has a market cap of $13.35 billion, a price-to-earnings ratio of 12.06, a P/E/G ratio of 0.68 and a beta of 0.91. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.94 and a 52 week high of $30.46. The firm’s 50-day simple moving average is $23.24 and its two-hundred day simple moving average is $24.40.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.16. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. As a group, equities analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on FMS shares. Erste Group Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Finally, Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.